Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,660 across all filing types
Latest filing 2024-08-09 Regulatory Filings
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
Please find attached intimation of loss of share certificates
Regulatory Filings
2024-08-09 English
Loss of Share Certificates
Regulatory Filings
2024-08-09 English
Board Meeting — MOREPEN LABORATORIES LIMITED has informed the Exchange about Board Meeting to be held on 12-Aug-2024 to inter-alia consider and approve the Unaudited Financial results of the Company…
Regulatory Filings
2024-08-08 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding a rectification about a previously announced Board Meeting. It clarifies that the proposal for declaration of final dividend and record date was not placed before the Board of Directors in the earlier meeting. The document is short (2256 characters) and serves as an intimation or correction notice rather than containing any financial results or detailed report. It does not contain actual financial data or detailed report content but is a regulatory disclosure related to board meeting agenda changes. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance disclosure.
2024-08-08 English
Purpose of the meeting has been revised
Board/Management Information Classification · 95% confidence The document is a letter addressed to stock exchanges regarding a rectification about a previously scheduled Board Meeting. It clarifies that the proposal for declaration of final dividend and record date were not placed before the Board of Directors as earlier intimated. The letter is an intimation or announcement related to board meeting agenda changes and compliance disclosures under SEBI (LODR) Regulations. It does not contain any financial results, detailed report, or data. The document length is short (2256 characters) and it is an announcement rather than a report. Therefore, it fits best under Board/Management Information (MANG) as it relates to board meeting information and corrections to prior disclosures.
2024-08-08 English
Please find attached intimation of loss of share certificates
Regulatory Filings
2024-08-07 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.